Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 1998

View Archived Issues

CP-320626, an antidiabetic agent with a novel mechanism of action

WAY-135201, a potassium channel opener for the treatment of diabetic neuropathy

Data safety monitoring board recommends continuation of Remune phase III trial

Miravant and Pharmacia & Upjohn amend Purlytin agreements

Santen presents new LTA4 hydrolase inhibitors

Isis and Merck & Co. establish collaboration for hepatitis C

NeoPharm announces positive phase I clinical trial results with LED

Neurocrine Biosciences acquires Northwest Neurologic

Cortecs launches new biopharmaceutical company

Spotlight on angiotensin II antagonists -- the top choice for long-term blood pressure control

Company Profile: AltaRex

Novartis selects somatostatin receptor-targeting antitumor compound for clinical testing

DNA constructs encoding HIV-1 genes induce cellular cytotoxicity in humans

Proof of clinical efficacy of repaglinide presented at diabetes meeting

Viagra is safe and effective in diabetic patients with ED

Low-molecular-weight heparin effective in cutaneous lichen planus

More on Exocell's antiglycation agent EXO-226

Entacapone receives favorable opinion from CPMP

New target for cardioprotection: the adenosine A3 receptor

Additional trial data requested by FDA for Dermagraft

Spartaject busulfan enters phase I for treatment of neoplastic meningitis

SangStat acquires Pasteur Merieux Connaught's organ transplant business

Rizatriptan safe and effective for migraine and migraine recurrence

AmBisome label expanded in Spain

Study reveals molecular target for tuberculosis treatment

GA-0113, a new-generation angiotensin II antagonist with clinical potential

Lubeluzole appears effective for early treatment of mild to moderate acute ischemic stroke